Showing results (531-540 of 553) with videos related to

Sort By:
Pageof 56
Journal of Geophysical Research. Biogeosciences|October 17, 2022
The Spectral Species Concept in Living ColorDuccio Rocchini, Maria J Santos, Susan L Ustin, et al.
Frontiers in Immunology|July 22, 2024
Sodium levels and immunotherapy efficacy in mRCC patients with bone metastases: sub analysis of Meet-Uro 15 studyMartina Catalano, Sara Elena Rebuzzi, Marco Maruzzo, et al.
JAMA Network Open|November 27, 2023
Sodium Levels and Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving NivolumabMartina Catalano, Sara Elena Rebuzzi, Marco Maruzzo, et al.
Clinical Genitourinary Cancer|May 14, 2018
Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access ProgramGiuseppe Procopio, Michele Prisciandaro, Roberto Iacovelli, et al.
The Journal of Allergy and Clinical Immunology|September 7, 2021
Antibody responses to the SARS-CoV-2 vaccine in individuals with various inborn errors of immunityOttavia M Delmonte, Jenna R E Bergerson, Peter D Burbelo, et al.
ESMO Open|August 30, 2017
Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study)Riccardo Ricotta, Antonella Verrioli, Silvia Ghezzi, et al.
Methods in Ecology and Evolution|July 15, 2021
rasterdiv-An Information Theory tailored R package for measuring ecosystem heterogeneity from space: To the origin and backDuccio Rocchini, Elisa Thouverai, Matteo Marcantonio, et al.
Cancer Immunology, Immunotherapy : CII|July 2, 2024
Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 studyCarlo Messina, Martina Catalano, Giandomenico Roviello, et al.
Frontiers in Oncology|February 27, 2024
Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 studyVeronica Murianni, Alessio Signori, Sebastiano Buti, et al.
Frontiers in Oncology|March 6, 2026
Impact of bone-targeting agents on the clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab: a sub-analysis of the Meet-URO 15 studyFrancesco Pantano, Andrea Malgeri, Ugo De Giorgi, et al.
Pageof 56